Related Experiment Video

Updated: Apr 26, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

26.7K

Intestinal microbiota transplantation, a simple and effective treatment for severe and refractory Clostridium

Hadeel Zainah1, Mona Hassan, Laila Shiekh-Sroujieh

  • 1Department of Infectious Diseases, Henry Ford Health System, Detroit, MI, USA.

Digestive Diseases and Sciences
|July 24, 2014
PubMed
Abstract

Insights

Intestinal microbiota transplantation (IMT) is a safe and effective treatment for severe, recurrent Clostridium difficile infection (CDI). This method, administered via nasogastric tube (NGT), successfully cured 79% of patients and prevented CDI recurrence.

Area of Science:

  • Gastroenterology
  • Infectious Diseases
  • Microbiome Research

Background:

  • Recurrent Clostridium difficile infection (CDI) poses a significant challenge, often refractory to conventional therapies.
  • Intestinal microbiota transplantation (IMT) has shown promise in restoring gut flora and treating CDI.
  • Limited data exists on IMT for severe or fulminant CDI cases.

Purpose of the Study:

  • To evaluate the efficacy and safety of IMT as a treatment for severe, refractory CDI.
  • To assess IMT's impact on CDI recurrence and short-term mortality.

Main Methods:

  • Retrospective analysis of 14 patients with severe CDI treated with IMT via nasogastric tube (NGT).
  • Donor stool was homogenized, filtered, and instilled via NGT.
  • Primary outcome: clinical cure (≤3 loose stools/day at day 7, no further CDI therapy).
  • Secondary outcomes: CDI recurrence within 100 days, 30-day mortality.

Main Results:

  • Eleven out of 14 patients (79%) achieved clinical cure after IMT.
  • No recurrence was observed in responders within the 100-day follow-up.
  • IMT was well-tolerated, with no CDI- or procedure-related deaths.
  • 30-day all-cause mortality was 29%, attributed to underlying comorbidities (cancer).

Conclusions:

  • Bedside IMT via NGT is an effective and safe therapeutic option for severe, refractory CDI.
  • IMT demonstrates a significant clinical cure rate and prevents recurrence in CDI patients.
  • The procedure is well-tolerated, with mortality linked to underlying conditions rather than CDI or IMT.

More Related Videos

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.6K
Murine Fecal Isolation and Microbiota Transplantation07:32

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

5.6K

Related Concept Videos

Microbiota of the Large Intestine01:27

Microbiota of the Large Intestine

The large intestine hosts the most densely populated microbial ecosystem in the human body. This complex community primarily consists of anaerobic bacteria, with Bacillota (formerly Firmicutes) and Bacteroidota (formerly Bacteroidetes) as the predominant groups. The distribution of these microbes varies along different sections of the large intestine, influenced by local environmental factors such as oxygen availability and nutrient composition.The cecum, located at the beginning of the large...
94
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
999
Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from...
60
Introduction to the Human Microbiota01:22

Introduction to the Human Microbiota

Microorganisms colonize various regions of the human body, including the mouth, nasal passages, throat, stomach, intestines, urogenital tract, and skin. The total number of microbial cells is estimated to range from 10¹³ to 10¹⁴—comparable to, or exceeding, the number of human somatic cells. This host–microbiome relationship has led to the conceptualization of humans as supraorganisms, wherein microbial communities perform vital roles in development, immunity,...
162
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.4K
What is Monogastric Digestion?01:50

What is Monogastric Digestion?

The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
56.2K